Skip to main content

Table 5 Univariate (5a) and multivariate analysis (5b) for PFS and OS

From: Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma

      PFS     OS  
  n risk n events 1 year-PFS (%) (± SE) p 1 year-OS (%) (± SE) p
a       
PS       
0–1 22 21 50 ± 10.7 0.001 63.6 ± 10.3 0.006
2–3 8 7 0   15.6 ± 14.2  
Age       
≤68 years 15 14 58.2 ± 13.1 0.06 79.4 ± 10.6 0.017
>68 years 15 14 20 ± 10.3   26.7 ± 11.4  
Sex       
M 19 18 31.8 ± 14.9 0.3 52.6 ± 11.5 0.4
F 11 10 42.1 ± 11.3   60.6 ± 15.4  
Group 1 24 22 31.1 ± 9.7 0.17 44 ± 10.4 0.11
Group 2 6 6 66.7 ± 19.2   83.3 ± 15.2  
T stage       
T1-2 3 2 66.7 ± 27.2 0.2 66.6 ± 27.2 0.25
T3-4 18 17 18.3 ± 9.5   35.9 ± 11.7  
N stage       
N0 11 9 31.8 ± 14.9 0.8 41.6 ± 15.6 0.7
N1 11 11 27.3 ± 13.4   45.5 ± 15  
Bismuth       
I-II 9 8 33.3 ± 15.7 0.9 44.4 ± 16.6 0.6
III-IV 15 14 29.3 ± 12.2   43.3 ± 13.3  
Tumor size ≤ 36 mm 12 10 27.8 ± 13.6 0.8 36.7 ± 14.6 0.3
>36 mm 9 9 33.3 ± 15.7   55.6 ± 16.6  
Chemotherapy       0.15
Yes 18 18 44.4 ± 11.7 0.3 66.7 ± 11.1
No 12 10 28.6 ± 13.8   27.5 ± 13.5
b   
    PFS     OS  
factors HR [CI95%] p HR [CI95%] p
PS 0–1 vs 2-3 3.9 [1.4-11.1] 0.01 3.9 [1.4-10.9] 0.01
Age ≤68 years vs >68 years 1.5 [0.56-4] 0.4 4.9 [1.2-18.9] 0.02
Group 1 vs 2 0.7 [0.2-2.3] 0.6 0.8 [0.2-2.] 0.7
Chemotherapy yes vs no _ _ 2.4 [0.7-8.2] 0.16
  1. Abbreviations: PS, performance status; SE standard error; T stage and N stage according to TNM classification; Bismuth: Bismuth classification; vs: versus; CI 95%: 95% Confidence interval.